Pay in 4 interest-free payments of $5.01 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
In 2024 semaglutide (Wegovy) became the first weight loss drug to also be approved for the reduction of risk of serious cardiovascular events in patients with cardiovascular (CV) disease and obesity and overweight
Our patients get regular check-ins, 24/7 messaging access, and real support because this journey isnt just physical, its emotional too
Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1, NEJM 2022, n=2,539) FDA DailyMed (current GLP-1 prescribing information) Mayo Clinic Prescription weight-loss drugs MeAgain App Store listing What MeAgain users say about tracking GLP-1 What Our Users Say I've been using the app for about 7 months now and I love how I'm able to track my meals and my daily medication
"Food and Drug Administration
The BISAP score, meanwhile, offers a favorable balance between simplicity and predictive capability
US$ 28.24
US$ 24.84
US$ 28.23
US$ 21.09
